SER Valuation

Serina Therapeutics Inc

Add to Watchlist

Advanced Chart

5.320

+0.19(3.704%)1D

Overview
Forecast
Valuation
Earnings

SER Relative Valuation

SER's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SER is overvalued; if below, it's undervalued.

Historical Valuation

Serina Therapeutics Inc (SER) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.09. The fair price of Serina Therapeutics Inc (SER) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：5.13

Fair

-3.20

Trailing

Forward

0.00

EV/EBITDA

Serina Therapeutics Inc. (SER) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-2.02

EV/EBIT

Serina Therapeutics Inc. (SER) has a current EV/EBIT of -2.02. The 5-year average EV/EBIT is -0.68. The thresholds are as follows: Strongly Undervalued below -2.57, Undervalued between -2.57 and -1.63, Fairly Valued between 0.26 and -1.63, Overvalued between 0.26 and 1.21, and Strongly Overvalued above 1.21. The current Forward EV/EBIT of -2.02 falls within the Undervalued range.

0.00

Serina Therapeutics Inc. (SER) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-2.27

P/OCF

Serina Therapeutics Inc. (SER) has a current P/OCF of -2.27. The 5-year average P/OCF is -0.82. The thresholds are as follows: Strongly Undervalued below -3.10, Undervalued between -3.10 and -1.96, Fairly Valued between 0.32 and -1.96, Overvalued between 0.32 and 1.46, and Strongly Overvalued above 1.46. The current Forward P/OCF of -2.27 falls within the Undervalued range.

-2.01

P/FCF

Serina Therapeutics Inc. (SER) has a current P/FCF of -2.01. The 5-year average P/FCF is -0.71. The thresholds are as follows: Strongly Undervalued below -2.82, Undervalued between -2.82 and -1.76, Fairly Valued between 0.34 and -1.76, Overvalued between 0.34 and 1.39, and Strongly Overvalued above 1.39. The current Forward P/FCF of -2.01 falls within the Undervalued range.

Serina Therapeutics Inc (SER) has a current Price-to-Book (P/B) ratio of -16.59. Compared to its 3-year average P/B ratio of 3.73 , the current P/B ratio is approximately -544.85% higher. Relative to its 5-year average P/B ratio of 3.73, the current P/B ratio is about -544.85% higher. Serina Therapeutics Inc (SER) has a Forward Free Cash Flow (FCF) yield of approximately -30.65%. Compared to its 3-year average FCF yield of -22.14%, the current FCF yield is approximately 38.42% lower. Relative to its 5-year average FCF yield of -22.14% , the current FCF yield is about 38.42% lower.

-17.20

P/B

Median3y

3.73

Median5y

3.73

-29.81

FCF Yield

Median3y

-22.14

Median5y

-22.14

Competitors Valuation Multiple

The average P/S ratio for SER's competitors is 0.37, providing a benchmark for relative valuation. Serina Therapeutics Inc Corp (SER) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 154.90%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SER.A

Serina Therapeutics Inc

Where Food Comes From Inc

Trident Digital Tech Holdings Ltd

Loss

56.11M

AACG.O

ATA Creativity Global

Performance Decomposition

Market capitalization of SER decreased by 21.76% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 51.00K to 130.00K.

The secondary factor is the P/E Change, contributed -27.69%to the performance.

Overall, the performance of SER in the past 1 year is driven by Revenue Growth. Which is more sustainable.

154.90%

51.00K → 130.00K

Revenue Growth

-148.97%

10.15K → -4.97K

Margin Expansion

-27.69%

-5.49 → -3.97

P/E Change

-21.76%